chromosome 11 open reading frame 42Genealiases: []
Q-omics provides the consensus-scored C11orf42 profile across patient tissues and cancer cell-line models. C11orf42 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C11orf42 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, C11orf42 RNA expression shows 19,346 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, BLCA, and THYM as cancer lineages where C11orf42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf42 survival associations across molecular data types. C11orf42 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf42 RNA expression–survival associations across cancer types. High C11orf42 expression shows unfavorable associations in THCA and KICH, but favorable associations in HNSC, SCLC, UCS and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for C11orf42 RNA expression.
This table summarizes C11orf42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for C11orf42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf42 shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, CHOL, STAD and HNSC. The BLCA box plot shows higher C11orf42 RNA expression in tumor versus normal tissue (log2 FC = +0.350, t-test p < 0.001).
This table shows molecular features associated with C11orf42 in patient tissues and cancer cell lines. In patient samples, C11orf42 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
